HOME >> MEDICINE >> NEWS
FDA approves EPZICOM

Research Triangle Park, NC August 2, 2004 - EPZICOMTM, a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration (FDA). EPZICOM combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), EPIVIR(R) (lamivudine, 3TC) and ZIAGEN(R) (abacavir sulfate, ABC) for use in combination with other antiretroviral drugs. The brand name, EPZICOM, is an acronym for EPIVIR and ZIAGEN in COMbination. EPZICOM Tablets are recommended for use in combination with antiretroviral drugs from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors.

GlaxoSmithKline (GSK), manufacturer of EPZICOM, announced today that it is initiating a voucher program for EPZICOM that will provide a 60 day supply of EPZICOM directly to patients at no cost. These vouchers will be available in limited supply through participating healthcare providers for a limited time. Vouchers can be used to initiate antiretroviral therapy for therapy-nave patients or for therapy-experienced patients who require a change in regimen.

"EPZICOM marks an important advance in GSK's ongoing commitment to provide new options in antiretroviral therapy for HIV patients," said Doug Manion, vice president for HIV Clinical Research for the Infectious Diseases Medicines Development Center (MDC) for GSK. "The voucher program will be particularly beneficial to people who are not covered by private health care plans or in specific states where the drug is not yet available on all formularies."

Dr. Manion added that EPZICOM provides patients and treaters with a flexible and potent dosing option that combines two NRTIs that have been widely used in antiretroviral therapy for years. "Prescribers are familiar with these medications, which have an established resistance and long-term safety p
'"/>

Contact: Annie Noland
anoland@pcipr.com
Public Communications Inc.
2-Aug-2004


Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves EPZICOM

(Date:8/31/2015)... ... August 31, 2015 , ... ... management device that could effectively deliver oxygen with a lower risk of failure," ... better way, I invented the Adam Device." , The Adam Device offers a ...
(Date:8/31/2015)... ... 2015 , ... A year ago this month, Seniors Guide first hit stands ... issue commemorating the successful first year. , “We started the magazine with the ... in their lives,” says Melissa Wolfert, founding Publisher for Seniors Guide Columbus. “Making the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... nonprofit authority on the use of health IT to create efficiencies in healthcare ... WEDI-Con 2015 . Taking place at the Hyatt Regency Reston in Reston, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Brooks Group, a global ... a department devoted to helping organizations identify and keep the best talent both ... The Brooks Group believes in offering a solution that goes beyond simply providing ...
(Date:8/31/2015)... ... August 31, 2015 , ... According to book reviewer ... Taking Charge of Your Life with Cancer is an excellent resource for everyone ... The Cancer Solution to be helpful in explaining what cancer is in a easy ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2
(Date:8/30/2015)... GENEVA, Switzerland , August 31, 2015 ... join healthbank to ... healthbank , the world,s first citizen-owned health data transaction ... and Netcetera to engineer and bring ...      (Logo: http://photos.prnewswire.com/prnh/20150828/261966) , "Our business ...
(Date:8/28/2015)... 28, 2015  Delays in the launch and ... down the decision-making process, resulting in missed opportunities ... for biopharmaceutical companies to develop a tactical approach ... quicker and more meaningful insights. ... nearly three-quarters of benchmarked study participants use review ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Bevacizumab Market ... by Roche under the trade name of Avastin, bevacizumab ... In Feb.26, 2010, it was approved by CFDA to ... China all come from Roche ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Bevacizumab Market 2015-2019 2
Cached News: